Courtney Andersen studies the role of estrogen receptor-alpha in ovarian cancer.
Chris Barnes investigates the structural details by which transcription factor activity regulates RNA Polymerase II during the universal process of eukaryotic gene expression.
Soma Jobaggy studies nitrated fatty acid pharmacology and the antioxidant response in hypertensive end-organ damage.
Allison Nagle studies growth factor receptor signaling in breast cancer.
Carola Neumann, MD
Associate Professor

Phone: 412-641-7725

MTA (comparable to baccalaureate degree) as Medical Technical Research Assistant, Naturwissenschaftliches Technikum Landau, i.d. Pfalz, Germany, 1989

MD, Ludwig-Maximilian's University, Medical School, Munich, Germany, 1997

Research Areas
Cancer Pharmacology
Pharmacology of Cell and Organ Systems
Redox Pharmacology
Signal Transduction
Photo of Carola Neumann, MD

The main interest of the Neumann laboratory is to expand our knowledge of cell signaling that is mediated by is in part mediated by oxidation and reducing (redox) reactions. As reactive oxygen species (ROS) deregulate the redox homeostasis and promote tumor formation by initiating an aberrant induction of signaling networks that cause tumorigenenesis, including breast cancer. To investigate the specific mechanisms underlying redox-induced tumorigenesis, the Neumann laboratory focuses on redox-induced posttranslational modifications (PTM) of protein cysteines, which play an important part in cell signaling. Peroxiredoxin 1 (PRDX1) is a peroxidase that has emerged as an important protein in cell signaling as it scavenges the second messenger H2O2, binds to and regulates signaling proteins and when knocked out in mice causes a variety of cancers, including breast cancer. Therefore, studying PRDX1 is an ideal model to further our understanding in redox-regulated cell-signaling pathways in breast cancer with the goal to utilize redox-induced PTMs as novel drug-targets in breast cancer therapy.
All of these studies include many aspects of translational breast cancer research utilizing basic biochemistry, molecular and cell biology, cell lines, mouse models and clinical samples.

Since its founding in 2014, Dr. Neumann is co-director of the breast cancer research advocacy network (bcRAN). The mission of bcRAN is to build a partnership between breast cancer survivors, covivors, previvors and scientists to accelerate the progress of cancer research.

bcRAN is part of UPMC Hillman Cancer Center, Womens Cancer Research Center (WCRC) and Magee Womens Hospital

Important Publications
Hopkins B, Nadler M, Skoko J, Bertomeu T, Pelosi A, Mousavi Shafaei P, Levine K, Schempf A, Pennarun B, Yang B, Datta D, Oesterreich S, Yang D, Rizzo M, Khosravi-Far R and Neumann CA. A PRDX1-specific redox regulation of the novel FOXO3 miRNA target let-7. Antioxidants and Redox Signaling 28:62-77, 2018.
Turner-Ivey B, Manevich Y Schulte J, Kistner-Griffin E, Jezierska-Drutel A, Yusen L and Neumann CA. A role for Prdx1 in specific redox-regulation of signaling in breast cancer-associated senescence. Oncogene 32:5302-5314, 2013.
Jezierska-Drutel A, Rosenzweig S and Neumann CA.  Role of oxidative stress and microenvironment in breast cancer development and progression.  Advances in Cancer Research 119:107-125, 2013.
Rani V, Neumann CA, Schulte, J. Shao C andTischfield JA. Prdx1 deficiency in mice promotes tissue specific loss of heterozygosity mediated by deficiency in DNA repair and increased oxidative stress. Mutation Research 735:39-45, 2012.
Neumann CA, Cao J and Manevich Y. Peroxiredoxin 1 and its role in cell signaling. Cell Cycle 8: 4072-4078, 2009.
Cao J, Schulte J, Knight A, Leslie NR, Zagozdzon A, Bronson R, Manevich Y, Beeson C and Neumann CA. Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J 28: 1505-1517, 2009.
Neumann CA, Krause DS, Carman CV, Das S, Dubey DP, Abraham JL, Bronson RT, Fujiwara Y, Orkin SH and Van Etten RA. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 424:561-565, 2003.


6/28/2019 9:00 AM Graduate Student Summer Seminar
Graduate Student Summer Seminar presented by Braulio Bonilla and Nolan Carew

Pharmacology and Chemical Biology Event Calendar

Program Achievements

Molecular Pharmacology Graduate Program Ranked #2 in National Research Council Rankings


Time to dissertation Defense
, last five graduating classes:  4.6 years, Completion Rate: 86.49%

First Author Publications (All students, past 5 year mean):  2.03;   Total Publications: 5.10

F-series Grants (F30/F31) (All Students, past 5 year mean):  12/34 (35%) 

Ranked #9 in National of Institute of Health funding of departments of Pharmacology

Ranked in the top 15 in funding for twenty-four consecutive years

Back to Top